'Warren Urges FTC to Probe Deal That Would Give Novo Nordisk Control of Some Catalent Plants; At Issue Is Whether the Deal Would Give Novo an Unfair Advantage in the Market for Obesity, Diabetes Drugs' - STAT News
'Warren Urges FTC to Probe Deal That Would Give Novo Nordisk Control of Some Catalent Plants; At Issue Is Whether the Deal Would Give Novo an Unfair Advantage in the Market for Obesity, Diabetes Drugs' - STAT News
U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission "closely scrutinize" a $16.5 billion deal in which Novo Nordisk's parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.
美國參議員伊麗莎白·禾倫已要求聯邦貿易委員會「密切審查」一項165億美元的交易，根據這項交易，諾和諾德的母基金會將收購合同藥品製造商龍翔，這引發了人們對這筆收購可能給這家制藥公司在用於治療肥胖和糖尿病的藥物蓬勃發展市場中帶來不公平競爭優勢的擔憂。
In a letter dated Wednesday, Warren noted that Catalent fills and packages syringes and injection pens for Novo Nordisk and other drug manufacturers, including its biggest rival, Eli Lilly, which sells competing medications and also contracts with Catalent to fill and package its drugs. She noted that Eli Lilly has described Catalent as an "integral" player in its manufacturing of diabetes and obesity drugs.
禾倫在週三的一封信中指出，龍翔爲諾和諾德及其他藥品製造商（包括其最大的競爭對手禮來公司）灌裝和包裝注射器和注射筆。她指出，禮來公司將龍翔描述爲其生產糖尿病和肥胖藥物的「重要」參與者。
"I am concerned that Novo Nordisk's merger with Catalent will give Novo Nordisk unprecedented visibility into and control over its competitor's production capacity, costs, and business practices, and the ability to preference its own products and obstruct its competitors' use of Catalent to produce" the drugs, she wrote. The drugs belong to a class of medicines known as GLP-1s.
她寫道：「我擔心諾和諾德與龍翔的合併將使諾和諾德能夠前所未有地了解和控制其競爭對手的生產能力、成本和業務實踐，並能夠優先選擇其自身產品並阻礙其競爭對手使用龍翔生產這些藥物。」這些藥物屬於一類被稱爲GLP-1的藥物。
譯文內容由第三人軟體翻譯。
